Practical Recommendations on Quantifying and Interpreting Treatment Effects in the Presence of Terminal Competing Risks: A Review
- PMID: 34851356
- DOI: 10.1001/jamacardio.2021.4932
Practical Recommendations on Quantifying and Interpreting Treatment Effects in the Presence of Terminal Competing Risks: A Review
Abstract
Importance: In a comparative trial, the time to a clinical event is often a key end point. However, the occurrence of a terminal event, such as death or premature study discontinuation, may preclude observation of this outcome. Although various methods for handling competing risks are available, no specific recommendations have been made for scenarios encountered in practice, especially when the terminal event profiles of the study arms are dissimilar. Moreover, appropriate methods for a desirable outcome, such as live hospital discharge, have seldom been discussed.
Observations: Several of the most commonly used methods are reviewed. The first regards the terminal event as censoring and applies standard survival analysis to the event of interest. The between-group difference is usually summarized by the cause-specific hazard ratio. This summary measure is inappropriate when the new therapy markedly prolongs time to the terminal event. Moreover, the corresponding Kaplan-Meier curve for the end point of interest is uninterpretable. The second method is to use the cumulative incidence curve, which is the probability of experiencing the event of interest by each time point, acknowledging that patients who have died will never experience the event. However, the resulting pseudo hazard ratio is difficult to interpret. With a proper alternative summary measure, this approach works well for a desirable outcome but may not for an undesirable outcome. The third method focuses on the event-free survival time by combining information from occurrences of the terminal event and the event of interest simultaneously. This clinically interpretable method naturally accounts for differences in terminal event rates when comparing treatments with respect to the time to an undesirable outcome.
Conclusions and relevance: This article enhances our understanding of each method's advantages and shortcomings and assists practitioners in choosing appropriate methods for handling competing risk problems in practice.
Similar articles
-
Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.Clin Trials. 2012 Oct;9(5):570-7. doi: 10.1177/1740774512455464. Epub 2012 Aug 22. Clin Trials. 2012. PMID: 22914867 Free PMC article.
-
A note on competing risks in survival data analysis.Br J Cancer. 2004 Oct 4;91(7):1229-35. doi: 10.1038/sj.bjc.6602102. Br J Cancer. 2004. PMID: 15305188 Free PMC article. Review.
-
Overestimation of the probability of death on peritoneal dialysis by the Kaplan-Meier method: advantages of a competing risks approach.BMC Nephrol. 2012 May 30;13:31. doi: 10.1186/1471-2369-13-31. BMC Nephrol. 2012. PMID: 22646159 Free PMC article.
-
Kaplan-Meier Survival Analysis Overestimates the Risk of Revision Arthroplasty: A Meta-analysis.Clin Orthop Relat Res. 2015 Nov;473(11):3431-42. doi: 10.1007/s11999-015-4235-8. Clin Orthop Relat Res. 2015. PMID: 25804881 Free PMC article. Review.
-
Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications.Med Care. 2010 Jun;48(6 Suppl):S96-105. doi: 10.1097/MLR.0b013e3181d99107. Med Care. 2010. PMID: 20473207 Review.
Cited by
-
Oral anticoagulant decreases stroke recurrence in patients with atrial fibrillation detected after stroke.Front Cardiovasc Med. 2022 Jul 22;9:929304. doi: 10.3389/fcvm.2022.929304. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35935644 Free PMC article.
-
Accounting for Competing Events When Evaluating Long-Term Outcomes in Survivors of Critical Illness.Am J Respir Crit Care Med. 2023 Dec 1;208(11):1158-1165. doi: 10.1164/rccm.202305-0790CP. Am J Respir Crit Care Med. 2023. PMID: 37769125 Free PMC article.
-
Revisiting the hazards of hazard ratios through simulations and case studies.Eur J Epidemiol. 2025 Jun;40(6):611-629. doi: 10.1007/s10654-025-01245-6. Epub 2025 Jul 3. Eur J Epidemiol. 2025. PMID: 40608267 Free PMC article.
-
Assessing treatment effects with adjusted restricted mean time lost in observational competing risks data.BMC Med Res Methodol. 2024 Aug 26;24(1):186. doi: 10.1186/s12874-024-02303-5. BMC Med Res Methodol. 2024. PMID: 39187791 Free PMC article.
-
Informative Censoring-A Cause of Bias in Estimating COVID-19 Mortality Using Hospital Data.Life (Basel). 2023 Jan 11;13(1):210. doi: 10.3390/life13010210. Life (Basel). 2023. PMID: 36676159 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources